// App-Quantinova.ai

: Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Researchers

Presenter

  • Nirav N. Shah

Principal Investigators

  • Jennifer R. Brown

  • Krish Patel

  • Jennifer A. Woyach

  • William G. Wierda

  • Chaitra S. Ujjani

  • Toby A. Eyre

  • Pier Luigi Zinzani

  • Alvaro J. Alencar

  • Thomas Gastinne

  • Paolo Ghia

  • Nicole Lamanna

  • Marc Hoffmann

  • Manish R. Patel

  • Ian W. Flinn

  • James N. Gerson

  • Shuo Ma

  • Catherine C. Coombs

  • Chan Y. Cheah

  • Ewa Lech-Maranda

  • Bita Fakhri

  • Won-Seog Kim

  • Minal A. Barve

  • Jonathon B. Cohen

  • Wojciech Jurczak

  • Talha Munir

  • Meghan C. Thompson

  • Lindsey E. Roeker

  • Katherine Bao

  • Nicholas A. Cangemi

  • Jennifer F. Kherani

  • Richard A. Walgren

  • Hongmei Han

  • Amy S. Ruppert

  • Anthony R. Mato

Medical Centers

  • Division of Hematology and Oncology, University of California, San Francisco, CA

  • New York-Presbyterian Columbia University Medical Center, New York, NY

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

  • Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

  • New York-Presbyterian/ Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

  • Winship Cancer Institute, Emory University, Atlanta, GA

  • Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL

  • Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

  • The University of Texas M.D. Anderson Cancer Center, Houston, TX

  • Department of Haematology, St James's University Hospital, Leeds, United Kingdom

  • Mary Crowley Cancer Research Center, Dallas, TX

  • MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA

  • Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

  • Indianapolis, IN

  • Sarah Cannon Research Institute, Nashville, TN

  • Lymphoma Program, Abramson Cancer Center, Philadelphia, PA

  • Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

  • Medical College of Wisconsin, Brookfield, WI

  • The University of Kansas Cancer Center, Kansas City, KS

  • Hematology Department, Nantes University Hospital, Nantes, France

Locations

  • United States

  • United Kingdom

  • Republic of South Korea

  • Australia

  • Italy

  • Poland

  • France

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Safety

  • Multicenteric

  • Tolerability

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved